Stock Analysis

Exploring Three High Growth Tech Stocks for Potential Portfolio Enhancement

TSX:CTS
Source: Shutterstock

As global markets experience a rebound, driven by easing core U.S. inflation and strong bank earnings, major indices such as the S&P 500 and Nasdaq Composite have recorded significant gains. In this environment of cautious optimism, identifying high-growth tech stocks that align with current economic trends can be crucial for enhancing a portfolio's potential.

Top 10 High Growth Tech Companies

NameRevenue GrowthEarnings GrowthGrowth Rating
Exelixis62.05%20.47%★★★★★★
Yggdrazil Group30.20%87.10%★★★★★★
CD Projekt23.11%30.61%★★★★★★
Waystream Holding22.09%113.25%★★★★★★
Pharma Mar25.43%56.19%★★★★★★
Ascelia Pharma76.15%47.16%★★★★★★
Medley20.97%27.22%★★★★★★
Alkami Technology21.99%102.65%★★★★★★
Travere Therapeutics30.02%61.89%★★★★★★
Delton Technology (Guangzhou)20.25%29.52%★★★★★★

Click here to see the full list of 1225 stocks from our High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Seegene (KOSDAQ:A096530)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Seegene, Inc. is a company that manufactures and sells molecular diagnostics products globally, with a market cap of ₩1.14 trillion.

Operations: Seegene generates revenue primarily through the sale of diagnostic kits and equipment, amounting to approximately ₩399.42 billion. The company's focus is on the global market for molecular diagnostics products.

Seegene has demonstrated a robust turnaround, transitioning from a net loss to reporting significant net income of ₩23.64 billion over the past nine months, reflecting an earnings surge by 35.21% per year. This growth outpaces the broader South Korean market's average and is underscored by an impressive annual revenue increase of 15.7%, which surpasses the domestic market's growth rate of 9.3%. The company's commitment to innovation is evident from its R&D investments, crucial in driving these financial improvements and positioning Seegene favorably within the biotech sector for continued expansion.

KOSDAQ:A096530 Revenue and Expenses Breakdown as at Jan 2025
KOSDAQ:A096530 Revenue and Expenses Breakdown as at Jan 2025

dely (TSE:299A)

Simply Wall St Growth Rating: ★★★★★★

Overview: dely inc. is engaged in planning, developing, managing, and operating various smartphone applications and web media with a market capitalization of ¥44.58 billion.

Operations: The company generates revenue primarily through its platform business, which contributes ¥9.90 billion. With a market capitalization of ¥44.58 billion, dely inc.'s operations focus on the development and management of smartphone apps and web media.

Following its recent IPO, dely has raised ¥15.15 billion, positioning itself strongly in the tech sector with a promising start on the financial markets. This strategic move is supported by an impressive forecast of annual revenue growth at 24.8% and earnings growth at 23.3%, significantly outpacing the Japanese market's averages of 4.3% and 8.1%, respectively. The company's dedication to innovation is highlighted by its substantial investment in R&D, essential for sustaining its rapid growth trajectory and enhancing its competitive edge in a dynamic industry environment.

TSE:299A Revenue and Expenses Breakdown as at Jan 2025
TSE:299A Revenue and Expenses Breakdown as at Jan 2025

Converge Technology Solutions (TSX:CTS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Converge Technology Solutions Corp. offers software-enabled IT and cloud solutions across the United States and Canada, with a market capitalization of approximately CA$658.24 million.

Operations: Converge Technology Solutions Corp. generates revenue primarily from its software-enabled IT and cloud solutions, with Portage SaaS Solutions contributing CA$13.69 million to its revenue streams.

Converge Technology Solutions, amid a challenging fiscal year with a net loss of CAD 168.54 million, has demonstrated resilience by repurchasing shares worth CAD 45.61 million, signaling confidence in its future prospects. Despite slower revenue growth at 1.3% annually compared to the industry average of 7.1%, the company is poised for a turnaround with expected profitability within three years and an impressive forecasted annual earnings growth rate of 125.21%. This strategic shift is underscored by significant R&D investments aimed at fostering innovation and securing competitive advantages in rapidly evolving tech landscapes.

TSX:CTS Earnings and Revenue Growth as at Jan 2025
TSX:CTS Earnings and Revenue Growth as at Jan 2025

Seize The Opportunity

Ready To Venture Into Other Investment Styles?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com